Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2022-05-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects the combination of Nivolumab and
Pemetrexed has on you and your cancer. The safety of this combination and the effectiveness
of this treatment will be studied.